

PRESS RELEASE

FOR IMMEDIATE RELEASE

**PHARMANIAGA SUSTAINS EARNINGS MOMENTUM WITH
RM32.2 MILLION PAT**

Key takeaways:

- *Higher Q1FY2026 revenue driven mainly by higher order volumes under the APPL.*
- *PAT's 6.4% growth reflects sustained profitability and lower finance costs.*

SHAH ALAM, 18 MAY 2026 – Pharmaniaga Berhad (Pharmaniaga or The Group) carried its recovery momentum firmly into financial year 2026 (FY2026), delivering a strong first quarter performance with profit after tax (PAT) of RM32.2 million for the quarter ended 31 March 2026 (Q1FY2026), reflecting the Group's strengthening fundamentals and continued operational resilience.

The performance represents another encouraging quarter for the Group, with PAT improving from RM30.2 million recorded in the same quarter last year, marking its ninth consecutive profitable quarter since Q1FY2024 and demonstrating the continued resilience of its operations. The growth was supported by stronger revenue contribution and sustained focus on operational efficiency.

Revenue for Q1FY2026 rose 11.7% to RM1.2 billion compared with RM1.1 billion recorded in Q1FY2025, driven by improved business activities across the Group. Profit before zakat and taxation also increased to RM46.4 million from RM45.5 million in the corresponding quarter last year.

The commendable performance was driven by higher demand from Government hospitals under the Approved Products Purchase List (APPL), sustained momentum within the Manufacturing Division, as well as lower finance costs arising from partial repayment of borrowings supported by effective inventory management.

Consequently, finance costs declined significantly by RM7.2 million, from RM17.3 million in the same period last year.

For the quarter under review, the Group is pleased to declare a first interim dividend of 0.25 sen per share in respect of the financial year ending 31 December 2026. The dividend will be paid on 3 July 2026 to shareholders whose names appear in the Register of Members as at the close of business on 8 June 2026.

This marks the Group's first dividend declaration since the third quarter of FY2022, reflecting the continued improvement in its financial performance and strengthening financial position.

Pharmaniaga Managing Director, Dato' Zulkifli Jafar, said, "Q1FY2026 marks an important milestone for Pharmaniaga as we are now turning the page from regularisation to growth, with renewed focus on strengthening our market standing, improving operational efficiency and pursuing sustainable long-term growth.

"The Group's Manufacturing Division continued to record encouraging progress during the quarter, encouraged by stronger demand for in-house manufactured products and improved operational performance across our facilities. At the same time, the Logistics and Distribution business registered higher order volumes under the expanded APPL, while our Indonesia operations maintained steady momentum, driven by stronger contributions from existing principals.

"We are also making steady progress in expanding both our biopharmaceutical and pharmaceutical portfolios. This includes advancements in human insulin and vaccine development, alongside the introduction of products in key therapeutic areas such as cardiovascular, urology and metabolic treatments. The planned launch of a new anti-diabetic product range in the coming quarter is expected to further strengthen our portfolio and support our expansion within the private healthcare segment," he said.

Dato' Zulkifli stated that there has been no direct disruption to medicine supply within the public healthcare system, regardless of the ongoing geopolitical and cost pressures arising from developments in the Middle East. The Group's inventory

position remains stable, supported by sufficient buffer stock levels to meet current demand nationwide.

“Nevertheless, we will remain cautious and vigilant as well as continue to work closely with the Government and relevant stakeholders to ensure the resilience, efficiency and reliability of the national healthcare supply chain,” he concluded.

-END-

About Pharmaniaga Berhad

Pharmaniaga is the pharmaceutical arm of Boustead Holdings Berhad Group of Companies, which together with the Armed Forces Fund Board, are the substantial shareholders of the Company. Listed on the Main Market of Bursa Malaysia Securities Berhad, Pharmaniaga’s core businesses are generic pharmaceuticals manufacturing; research and development; marketing and sales; warehousing and distribution of pharmaceutical and medical products. With a vision to be the premier Malaysian pharmaceutical company, its operations are strengthened by five manufacturing plants, as well as extensive logistics and distribution network in Malaysia and Indonesia. Pharmaniaga Group is positioned to be a regional player in the international pharmaceutical industry.

For more information, please visit <https://pharmaniaga.com/>.

Issued by Imej Jiwa Sdn Bhd on behalf of Pharmaniaga Berhad

For further media inquiries please contact:

Dato’ Zuhri Iskandar Kamarzaman (Pharmaniaga)

E-mail: zuhri@pharmaniaga.com

Telephone number: 03-3342 9999 ext. 434

Elizabeth Tan (Imej Jiwa)

E-mail: elizabeth@imejjiwa.com | Mobile: +6012 207 0993